From the Journals

Strictures in Crohn’s: Balloon dilation avoids later surgery


 

FROM EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY

Limiting factors

“This is an important study that really adds something to the literature,” noted Joseph Carmichael, MD, chief medical officer and chief of colon and rectal surgery at the University of California, Irvine. “The cohort is a little unusual in this area in that it encompasses a whole country. Yet this is exactly what makes the data stand apart from previous studies, since the patient population was unselected. That’s how you get a true incidence of the intervention.”

Joseph Carmichael, MD, chief medical officer and chief of colon and rectal surgery at UC Irvine Health.

Dr. Joseph Carmichael

Beyond the generally favorable outcomes associated with EBD, Dr. Carmichael highlighted similar rates of success across both primary and postsurgical strictures. “Some of the previous data suggest postsurgical strictures don’t do as well with endoscopic dilation, and this [study] seems to go against that,” he said. “Which really deserves a closer look.”

Reflecting on the researchers’ call for more frequent use of EBD in patients with Crohn’s disease, Dr. Carmichael speculated that several factors may be limiting current utilization in Europe and the U.S. For one, there may not be enough interventional gastroenterologists. Also, the procedure “generally requires a high-volume provider who’s got surgical backup because these [procedures] have a 2% to 4% incidence of technical failure – including perforation or bleeding. These risks may deter patients from undergoing the procedure.

“Patients with Crohn’s disease can be pretty remarkable in their ability to endure obstruction,” he added. “If someone’s feeling their symptoms aren’t altering their quality of life, they may choose not to proceed with it.”

With all candidate patients, Dr. Carmichael recommended discussing the risks of EBD compared with the risks of declining the intervention, such as complete bowel obstruction, bowel perforation, or fistula. “That’s a question that needs to be included with every conversation when we discuss procedures,” he explained.

The researchers report that, among others, they have relationships with Janssen-Cilag, AbbVie A/S, and Celgene. Dr. Bruining and Dr. Carmichael reports no relevant conflicts of interest.

This article was updated 7/29/22.

Pages

Recommended Reading

High residual liver cancer risk in HCV-cured cirrhosis
MDedge Internal Medicine
New insights into worldwide biliary tract cancer incidence, mortality
MDedge Internal Medicine
Cutting dietary simple sugars may relieve GERD symptoms
MDedge Internal Medicine
Quicker remission with tofacitinib versus vedolizumab in ulcerative colitis: study
MDedge Internal Medicine
IBD in pregnancy: Ustekinumab, vedolizumab use appears safe
MDedge Internal Medicine
U.S. hot, cold spots of young-onset CRC may help target interventions
MDedge Internal Medicine
Eight must-read GI studies for the primary care physician
MDedge Internal Medicine
Moderate drinking shows more benefit for older vs. younger adults
MDedge Internal Medicine
Pre-endoscopy COVID-19 testing may not be needed
MDedge Internal Medicine
Does choice of biologic affect outcomes in perianal Crohn’s disease?
MDedge Internal Medicine